Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

Journal of Virology

Volumn 76, Issue 2, 2002, Pages 517-524

  Bradney, C P ^a   Sempowski, G D ^a   Liao, H X ^a   Haynes, B F ^a   Staats, H F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHOLERA TOXIN; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; PEPTIDE ANTIBODY; VIRUS PROTEIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FECES; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; VAGINA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; FEMALE; GENE PRODUCTS, ENV; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKINS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; SALIVA; VACCINES, SUBUNIT; VAGINA;

EID: 0036140236     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.2.517-524.2002     Document Type: Article

References (54)

1. Cytokine-in-adjuvant steering of the immune response phenotype to Hiv-1 vaccine constructs - Granulocyte-macrophage colony-stimulating factor and Tnf-alpha synergize with 11-12 to enhance induction of cytotoxic T lymphocytes
2. Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro
3. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
4. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
5. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen
6. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12
7. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL
8. Intracellular neutralization of Hiv transcytosis across tight epithelial barriers by anti-Hiv envelope protein dIgA or IgM
9. IL-12 is an effective adjuvant for induction of mucosal immunity
10. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity
11. The intestinal epithelial cell: Immunological aspects
12. Mucosal immunity and tolerance: Relevance to vaccine development
13. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells
14. Cholera toxin as a mucosal adjuvant
15. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys
16. Priming of anti-human immunodeficiency virus (HIV) CD8 + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides
17. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues
18. Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma
19. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to Hiv-1 Gp120
20. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: A local defense function for IgA
21. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope
22. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
23. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: Neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
24. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin
25. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
26. Intracellular neutralization of virus by immunoglobulin A antibodies
27. Human immunodeficiency virus (HIV)specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons
28. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
29. Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgery
30. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium
31. Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia
32. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells
33. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket
34. Phase 1 trial of recombinant human interleukin-1beta (rhIL-1beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology Group Study 8940
35. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer
36. A mucosal IgA-mediated excretory immune system in vivo
37. Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract
38. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
39. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin
40. Cytokine requirements for the induction of systemic and mucosal cytotoxic T lymphocytes after nasal immunization
41. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens
42. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-Hiv antibody responses
43. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
44. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes
45. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
46. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects
47. Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease
48. Interleukin-1 alpha administered after autologous transplantation: A phase I/II clinical trial
49. Mucosal tolerance: A two-edged sword to prevent and treat autoimmune diseases